反応式
[CH3:1][O:2][C:3]1[N:8]=[C:7](O)[CH:6]=[CH:5][CH:4]=1.[OH:10][CH:11]1[CH2:14][N:13]([C:15]2[CH:20]=[CH:19][C:18]([C@@H:21]([NH:23][C:24](=[O:26])[CH3:25])[CH3:22])=[CH:17][CH:16]=2)[CH2:12]1.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.N(C(OC(C)(C)C)=O)=NC(OC(C)(C)C)=O>C1COCC1>[CH3:1][O:2][C:3]1[N:8]=[C:7]([O:10][CH:11]2[CH2:12][N:13]([C:15]3[CH:16]=[CH:17][C:18]([C@@H:21]([NH:23][C:24](=[O:26])[CH3:25])[CH3:22])=[CH:19][CH:20]=3)[CH2:14]2)[CH:6]=[CH:5][CH:4]=1参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
反応条件
- 温度
- 60 °C
実験手順
To 13 mg (0.10 mmol) 6-methoxy-pyridin-2-ol in THF (1.0 mL) is added 23 mg (0.10 mmol) (S)—N-{1-[4-(3-hydroxy-azetidin-1-yl)-phenyl]-ethyl}-acetamide (V.1) in THF (1.0 mL). 29 mg (0.11 mmol) triphenylphosphine and 25 mg (0.11 mmol) di-tert-butyl azodicarboxylate are added and the mixture is stirred for 3 h at 60° C. Another portion of 29 mg (0.11 mmol) triphenylphosphine and 25 mg (0.11 mmol) di-tert-butyl azodicarboxylate are added and stirring is continued for 2 h at 60° C. The mixture is concentrated in vacuo and the residue is purified by HPLC (XBridge, acetronitrile/H2O (+0.1% NH4OH)) to yield the desired product.
後処理
- stirringstirring
- waitis continued for 2 h at 60° C
- concentrationThe mixture is concentrated in vacuo
- customthe residue is purified by HPLC (XBridge, acetronitrile/H2O (+0.1% NH4OH))
出典と根拠
- ORDレコード
- ord-ce8ea89526ca4ff2b99304cd8c6e6219
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08530461B2
関連ノート
読み込み中…